Outcomes and Diagnostic Processes in Outpatients with Presumptive Tuberculosis in Zomba District, Malawi. by van Lettow, Monique et al.
van Lettow, M; Bedell, R; Maosa, S; Phiri, K; Chan, AK; Mwin-
jiwa, E; Kwekwesa, A; Kawonga, H; Joshua, M; Harries, AD; van
Oosterhout, JJ (2015) Outcomes and Diagnostic Processes in Out-
patients with Presumptive Tuberculosis in Zomba District, Malawi.
PLoS One, 10 (11). e0141414. ISSN 1932-6203 DOI: 10.1371/jour-
nal.pone.0141414
Downloaded from: http://researchonline.lshtm.ac.uk/2352335/
DOI: 10.1371/journal.pone.0141414
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Outcomes and Diagnostic Processes in
Outpatients with Presumptive Tuberculosis in
Zomba District, Malawi
Monique van Lettow1,2*, Richard Bedell1, Sonia Maosa1, Kenneth Phiri1, Adrienne
K. Chan1,2,3, Edson Mwinjiwa1, Aunex Kwekwesa1, Harry Kawonga1, Martias Joshua4,
Anthony D. Harries5,6, Joep J. van Oosterhout1,7
1 Dignitas International, Zomba, Malawi, 2 Dalla Lana School of Public Health, University of Toronto,
Toronto, Canada, 3 Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of
Toronto, Toronto, Canada, 4 Zomba Central Hospital, Ministry of Health, Zomba, Malawi, 5 The International
Union against Tuberculosis and Lung Disease, Paris, France, 6 London School of Hygiene and Tropical
Medicine, London, United Kingdom, 7 Department of Medicine, College of Medicine, University of Malawi,
Blantyre, Malawi
*m.vanlettow@dignitasinternational.org
Abstract
Background
In Malawi, outpatients who have presumptive tuberculosis (TB), i.e. fever, night sweats,
weight loss and/or any-duration cough (HIV-infected) or cough of at least 2 weeks (HIV-
uninfected), are registered in chronic cough registers. They should receive a diagnostic
work-up with first-step provider-initiated HIV testing and sputum testing which includes
XpertMTB/RIF, following a national algorithm introduced in 2012.
Methods
An operational study, in which we prospectively studied 6-month outcomes of adult outpa-
tients who were registered in chronic cough registers in Zomba Central Hospital and Mata-
wale peri-urban Health Center, between February and September 2013. We recorded
implementation of the diagnostic protocol and outcomes at 6 months from registration.
Results
Of 348 patients enrolled, 165(47%) were male, median age was 40 years, 72(21%) had pre-
vious TB. At registration 154(44%) were known HIV-positive, 34(10%) HIV-negative (26
unconfirmed) and 160(46%) had unknown HIV status; 104(56%) patients with unknown/
unconfirmed HIV status underwent HIV testing. At 6 months 191(55%) were HIV-positive,
87(25%) HIV-negative (26 unconfirmed) and 70(20%) still had unknown HIV status. Higher
age and registration in Matawale were independently associated with remaining unknown
HIV status after 6 months. 62% of patients had sputum tested, including XpertMTB/RIF,
according to the algorithm. TB was diagnosed in 54(15%) patients. This was based on
XpertMTB/RIF results in 8(15%) diagnosed cases. In 26(48%) TB was diagnosed on clinical
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grounds. Coverage of ART in HIV-positive patients was 89%. At 6 months, 236(68%) were
asymptomatic, 48(14%) symptomatic, 25(7%) had been lost-to-follow-up and 39(11%) had
died. Mortality among those HIV-positive, HIV-negative and with unknown HIV-status was
15%, 2% and 10%, respectively. Male gender, being HIV-positive-not-on-ART and not
receiving antibiotics were independent risk factors for mortality.
Conclusion
HIV prevalence among patients with presumptive TB was high (55%). One quarter was not
HIV tested and mortality in this group was substantial (10%). The impact of XpertMTB/RIF
on TB diagnosis was limited.
Introduction
The HIV/AIDS epidemic has increased the global tuberculosis (TB) burden greatly. Early
detection of HIV infection among TB patients offers the opportunity to promptly link patients
to HIV care interventions, such as cotrimoxazole prophylactic treatment (CPT) and antiretro-
viral treatment (ART), which can reduce morbidity and mortality [1]. Consequently, attention
has focused on the necessity to coordinate TB and HIV/AIDS control programme services
more closely [2].
Mortality among patients with presumptive TB, also known as TB suspects, is high. In
Malawi, mortality rates among patients with presumptive TB range between 25–45% [3]. A
study conducted at Zomba Central Hospital in 2010, reported that 29% of patients with pre-
sumptive tuberculosis died during the period they were admitted to hospital and being investi-
gated for TB [4]. The same study also showed that of those who knew their HIV status (35%),
all were HIV-positive, and that only few patients with unknown HIV status received provider
initiated testing (PITC). High, undiagnosed, HIV-prevalence among patients with presumptive
TB is thought to be responsible for the mortality in this group.
In high HIV and TB burden settings such as Malawi, policy makers have agreed that PITC
should be promoted and provided not only to patients with active tuberculosis who register for
treatment, but also to patients with presumptive TB [5,6]. The revised 2012 National Tubercu-
losis Program (NTP) manual recommends offering routine opt-out HIV testing to active and
presumptive TB cases [7].
In Malawi, where the national adult HIV prevalence is 10% [8], TB cases are largely detected
through passive case finding. Patients are considered to have presumptive tuberculosis if they
report fever, night sweats, weight loss, and/or any-duration cough (HIV-infected persons) or
cough of at least 2 weeks duration (HIV-uninfected persons). At health facilities, such patients
are registered in standard chronic cough registers provided by the NTP. Patients with presump-
tive TB need to receive PITC and submit sputum specimens to health facility laboratories for
smear microscopy for acid-fast bacilli (AFB). Patients whose sputum smears are negative for
AFB should be managed according to an algorithm that includes empiric antibiotic treatment for
bacterial causes of respiratory infection, and chest radiography in order to determine whether or
not the patients have clinical/radiological evidence of smear-negative pulmonary TB.[7]
A rapid DNA-based method [XpertMTB/RIF] has demonstrated high sensitivity among
HIV infected smear-negative pulmonary TB cases [9]. The authors found sensitivity for detec-
tion of smear-negative pulmonary TB of 72.5%, 85.1% and 90.2% with one, two and three tests
per patient respectively. The use of XpertMTB/RIF would allow a more accurate diagnosis of
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smear-negative pulmonary TB, and have a beneficial effect on the diagnostic process for
patients with presumed tuberculosis, of whom a large proportion have associated HIV-
infection.
The revised 2012 NTP manual now recommends first-step provider-initiated HIV testing
(PITC) and the use of Xpert MTB/RIF in a new diagnostic algorithm for patients with pre-
sumptive TB. To explore the application of this new algorithm in a real-life setting, we prospec-
tively studied its implementation and the subsequent 6-month outcomes of patients registered
in chronic cough registers in two clinics in Zomba District.
Methods
Study design and setting
We conducted an observational cohort study of adult outpatients (16 years or older) in Zomba
Central Hospital (ZCH) and Matawale peri-urban Health Center (MHC), in the routine opera-
tional setting. We recruited participants at the point of registration in the chronic cough regis-
ters between February and September 2013. We recorded implementation of the diagnostic
protocol and outcomes at 6 months from registration. The study sites, ZCH and MHC were
purposively selected, because in both facilities an electronic patient unique identification sys-
tem has been introduced. This facilitates tracking of referrals between the outpatient depart-
ment and HIV and TB care services, but does not allow tracking referrals to other care services
such as HIV testing and counselling (HTC) or laboratory services within the same facility.
ZCH has XpertMTB/RIF facilities on-site, MHC sends samples to ZCH.
In 2012 a new diagnostic algorithm for presumptive TB patients was introduced in Malawi.
The algorithm directs that: a) XpertMTB/RIF is indicated as the primary sputum diagnostic
test for TB in patients with severe disease who need to be hospitalized, for retreatment cases
and for those with otherwise suspected multidrug resistant tuberculosis; and b) for all others,
XpertMTB/RIF should be reserved for when sputum is AFB negative [7]. If sputummicroscopy
and XpertMTB/RIF are negative, response to antibiotics and the result of a chest X-ray deter-
mine the diagnosis of smear negative pulmonary TB. National TB guidelines allow health facili-
ties without Xpert MTB/RIF on site, such as MHC, to pursue treatment of other causes of the
syndrome (mostly bacterial pneumonia and Pneumocystis pneumonia) before referring for
XpertMTB/RIF testing. National guidelines were followed for rapid HIV antibody testing [10],
and laboratory diagnostic sputum smear microscopy and Xpert MTB/RIF testing [7]. Microbi-
ologically confirmed TB was defined as at least one positive sputum smear examination, or if
Mycobacterium TB was identified from a sputum specimen by Xpert MTB/RIF.
Data collection
After written informed consent, a structured piloted and pre-tested questionnaire was used at
enrolment to ascertain socio-demographic characteristics, HIV status (if known), ART status
(if known HIV-infected) and duration of cough. In addition, mobile phone numbers and resi-
dence location information were collected to enable follow up data collection at 6 months from
registration.
Uptake and outcome variables were extracted from health facility registers (chronic cough
register, TB laboratory register, laboratory register for XpertMTB/RIF test, X-ray, HTC, TB,
ART) and where possible from the electronic data systems.
Primary outcomes of interest at 6-months from registration were alive, dead, and lost to fol-
low-up. Secondary outcomes included the number of adults registered in the chronic cough
register as diagnosed with active TB and the proportion that started anti-TB treatment, the
number diagnosed with HIV and the proportion who were referred to HIV services and who
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started ART. The time from being registered in the cough register to the initiation of treatment
of final diagnoses was also recorded.
Six months from time of registration/enrolment participants were contacted by phone and
asked to return to the health facility at an arranged date to conduct a second face-to-face inter-
view. In some cases, interviews were conducted by phone. If participants could not be reached
by phone, they were traced and interviewed at their place of residence.
At the 6-month follow up visit, a structured piloted and pre-tested questionnaire was used
to confirm and complete data on uptake and timing of HTC (referral and test results), diagno-
sis and uptake and timing of treatment for tuberculosis and HIV. Health passports were
reviewed (when available) to verify information. In addition, the outcomes alive without symp-
toms, alive and symptomatic, lost to follow up and death were recorded.
Data management and analysis
Data were double entered into a Microsoft Access database. Relevant data from the electronic
monitoring systems at the sites were extracted and merged into the database. Descriptive analy-
ses, using IBM SPSS Statistics 20 (IBM, Armonk, NY, USA) software, included medians with
interquartile ranges [IQR], and proportions to summarize the data. To explore factors associ-
ated with having an unknown HIV-status, binary logistic regression models were fitted with
having an unknown HIV-status at 6 months follow up (versus those having a confirmed
result), as the outcome variable. To explore factors associated with mortality, binary logistic
regression models were fitted with having died (versus being alive) within 6 months from regis-
tration in the chronic cough register as the outcome variable. Crude odds ratios (OR) and
adjusted odds ratios (aORs) with 95% CIs were calculated. Adjustment for the following vari-
ables took place in both models: gender, age, site of registration in the chronic cough register,
duration of cough and reported previous tuberculosis treatment. In addition, HIV (ART) sta-
tus, sputum AFB results, XpertMTB/RIF results, having started and time to initiation of TB or
antibiotic treatment were included in the model exploring associations with mortality. A signif-
icance level of 0.05 was set for all statistical testing.
Ethical approval
Ethical approval was granted by the National Health Sciences Research Committee, Malawi
(#1055) and the Ethics Advisory Group of the International Union Against Tuberculosis and
Lung Disease, Paris, France (#106/12). In the Malawi health system, the age group 15–24 are
defined as young adults, and were approved to be included in the study. However, only 2 par-
ticipants were under the age of 18 years old, for whom written guardian witness was sought.
Results
Characteristics of study participants
A total of 348 adults were enrolled in the study; 165 (47%) were male, the median age was 40
(IQR 32–50). The median duration of cough was 3 weeks (IQR 2–4) and 72 (21%) had received
prior TB treatment. Table 1 gives an overview of the characteristics of study participants and
HIV status ascertainment by facility.
HIV status ascertained from registration in chronic cough register
through 6-month follow up
At registration in both study sites 154 (44%) adults were known HIV positive, 34 (10%) were
HIV negative (8/34 confirmed) and 160 (46%) were HIV unknown. Between registration and
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the 6-month follow up point, 104 (56% of unknown and unconfirmed) underwent HIV testing.
At 6 months, a total of 191 (55%) adults were confirmed HIV positive, 61 (18%) confirmed
negative, 26 (7%) unconfirmed negative and 70 (20%) remained HIV unknown. Higher age
and registration in MHC were independently associated with remaining HIV unknown after 6
months (Table 2).
Tuberculosis diagnostic pathways
Fig 1 shows the laboratory evaluation conducted to identify pulmonary TB among the study
participants in both sites. Of 348 adults registered in the chronic cough registers, 323 reported
submission of sputum for microscopy. Of these, 319 AFB results were found in the TB labora-
tory registers (20 AFB+/299 AFB-). 12/20 (60%) of adults with a positive smear result were
HIV positive. Out of the 299 AFB negative smear results, 186 (62%) had XpertMTB/RIF fol-
lowing sputum smear examination according to the protocol (72% in ZCH; 24% in MHC).
Tuberculosis diagnosis was made in 54/348 (15%). In 8/54 (15%) cases the diagnosis was based
Table 1. Characteristics of study participants’ registered in chronic cough registers in Zomba Central Hospital and Matawale Health Centre
between February and September 2013.
Characteristics by facility at registration ZCH*n = 257 MHC*n = 91 Total n = 348
Male gender (n) % (114) 44% (51) 56% (165) 47%
Age (median; IQR) 39 (32–50) 40 (32–50) 40 (32–50)
Duration of cough in weeks (median; IQR) 3 (2–4) 3 (2–6) 3 (2–4)
Previous TB (n) % (57) 22% (15) 16% (72) 21%
HIV status at registration
HIV-infected (n) % (123) 48% (31) 34% (154) 44%
HIV-uninfected, conﬁrmed (n) % (6) 2% (2) 2% (8) 2%
HIV-uninfected, reported (n) % (26) 10% - (26) 8%
HIV status unknown (n) % (102) 40% (58) 64% (160) 46%
HIV status at 6 months follow-up
HIV-infected (n) % (152) 59% (39) 43% (191) 55%
HIV-uninfected, conﬁrmed (n) % (38) 15% (23) 25% (61) 17%
HIV-uninfected, reported (n) % (26) 10% - (26) 8%
HIV status unknown (n) % (41) 16% (29) 32% (70) 20%
* ZCH: Zomba Central Hospital; MCH: Matawale Health Centre
doi:10.1371/journal.pone.0141414.t001
Table 2. Factors associated with having an unknown HIV-status at 6 month follow up.
Univariate O.R. (95% C.I.) P-value Multivariate O.R. (95% C.I.)* P-value
Gender (Male) 1.41 (0.83–2.39) 0.20
Age (per year) 1.03 (1.01–1.05) 0.001 1.04 (1.02–1.06) 0.001
Site**:
ZCH - - - -
MHC 2.46 (1.42–4.28) 0.001 2.56 (1.42–4.62) 0.002
Duration of cough (in weeks) 1.00 (0.97–1.04) 0.88
Previous TB (yes) 0.69 (0.34–1.39) 0.30
* Adjusted for all other variables in the binary logistic regression model. In the multivariate analysis, only variables with signiﬁcant associations are shown.
** ZCH: Zomba Central Hospital; MCH: Matawale Health Centre
doi:10.1371/journal.pone.0141414.t002
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on the Xpert MTB/RIF result and in 26/54 (48%) TB treatment was started on the basis of clini-
cal diagnosis. 28/54 (52%) Patients had microbiologically confirmed TB diagnosis (20 AFB+
and 8 XpertMTB/RIF+); there were no cases of rifampicin resistance during Xpert MTB/RIF
testing.
6-month outcomes of patients with presumptive tuberculosis in ZCH and
MHC by diagnostic process and treatment uptake
Table 3 shows 6-months outcomes by site and HIV and ART status. At 6 months, 236 (68%) of
all patients were asymptomatic, 48 (14%) were symptomatic, 25 (7%) had been lost-to-follow-
up and 39 (11%) of all patients had died (12% in ZCH; 8% in MHC). Mortality among those
HIV-positive, HIV-negative and with unknown HIV-status was 15%, 2% and 10% respectively.
Table 4 provides details of the diagnostic processes, treatment uptake and time to treatment
of final diagnoses by HIV (ART) status, and subsequent 6-month outcomes. Coverage of ART
in confirmed HIV positive patients was 89%. TB treatment was started in 53/54 (98%) adults
diagnosed with TB and among those, 32/53 (60%) also received antibiotic treatment. There
were 219 presumed TB patients who received treatment for bacterial infection only, and for 76,
Fig 1. Laboratory tests conducted to identify pulmonary TB in adults registered in chronic cough registers in Zomba Central Hospital and
Matawale Health Centre.
doi:10.1371/journal.pone.0141414.g001
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no treatment was reported. In multivariate analysis, male gender, being HIV positive but not
on ART and not having started antibiotics were independent risk factors for mortality
(Table 5).
Discussion
We found that the HIV prevalence in Malawian adult TB suspects was 55%. This falls within a
range of studies on TB suspects from Kenya (n = 5457, HIV prevalence 62%, HIV unknown
11%), Uganda (n = 665, HIV prevalence 42%, HIV unknown 15% [11]), and Ethiopia (n = 506,
HIV prevalence 27%, HIV unknown 41% [12]). Despite differences in the design of the studies
and the study settings, our study confirms that HIV prevalence among presumptive TB
patients in sub-Saharan Africa is very high.
Because the high mortality among patients with presumed TB is believed to be associated
with undiagnosed HIV infection, the Malawi NTP changed their guidelines in 2012, placing
PITC as a prominent first step in the diagnostic algorithm. Probably due to this measure, HIV
testing uptake and the prevalence of known HIV status were improved (80% vs. 44%) com-
pared to our study in ZCH from 2011 [4]. This reflects growing experience with the introduc-
tion of PITC in various circumstances in resource limited settings, as summarized in a
systematic review [13]. However, we believe that the rate of unknown HIV status six months
after registration remained unacceptably high and there was substantial mortality in this group
(10%). It is likely that HIV prevalence in those with unknown HIV status was considerable and
that most would have been eligible for CPT and ART, both of which reduce mortality. In a sur-
vey in northern Malawi, more than 50% of HIV positive TB suspects were eligible for ART in
2006, when the CD4 threshold value for ART eligibility was lower than in the study period
(CD4<200 vs.<350 cells/μL) [14]. More effort is required to improve the uptake of HIV test-
ing among TB suspects to allow initiation of ART and CPT, possibly even before the diagnostic
work-up for TB has been completed [15]. In multivariate analysis, older age and being regis-
tered at MHC were associated with having unknown HIV status in our study. Factors such as
free of charge availability of both HIV testing and treatment (as present in our setting) have
earlier been identified as enablers to HIV testing [16]. We did not study the reasons why indi-
vidual participants were not tested and we were unable to determine important barriers to HIV
testing e.g. stigma, lack of a supportive social network (which may be more common in males)
and health system related issues such as stock-outs of HIV test kits. Importantly, presumptive
TB patients may not perceive themselves as being at high risk of HIV infection, which reduces
willingness to undergo testing [16]. The high HIV prevalence in our local setting could be com-
municated to this specific group of patients to increase the chance of HIV testing uptake.
Measures to improve uptake of HIV treatment among TB patients have been successful in
Malawi. Similar to the experience from South Africa [17], priority for PITC among patients
Table 3. Six-month outcomes of patients with presumptive tuberculosis in Zomba Central Hospital and Matawale Health Centre by HIV/ART
status.
Outcomes (n) % HIV+ on ART HIV+ not on
ART
HIV HIV status
Unknown
TOTAL
Alive asymptomatic (121) 72% (13) 62% (49) 80% (53) 55% (236) 68%
Alive symptomatic (18) 11% (1) 5% (11) 18% (18) 19% (48) 14%
Lost-to-follow-up (8) 5% (1) 5% (16) 16% (25) 7%
Died (22) 13% (6) 29% (1) 2% (10) 10% (39) 11%
Total 169 21 61 97 348
doi:10.1371/journal.pone.0141414.t003
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Table 4. Six-month outcomes of patients with presumptive tuberculosis in Zomba Central Hospital and Matawale Health Centre by diagnostic pro-
cess and treatment uptake.
Diagnostic process Treatment Uptake n = 348 Time to treatment,
median days (IQR)
HIV (ART)
status
LTF Alive Died
Sputum not submitted for
microscopy or not found,
Treatment for Bacterial
Infection only
17 0 (0–19) HIV+ on ART 8
N = 29 HIV+ not on
ART
3
HIV - 1
Unknown 5
No treatment reported 12 - HIV+ on ART 1 1 3 (60%)
HIV+ not on
ART
1
Unknown 3 1 2 (33%)
Smear microscopy (AFB) positive, TB treatment on basis of
AFB results
19 4 (1–11) HIV+ on ART 10 1 (9%)
N = 20 HIV - 6
Unknown 2
No treatment reported 1 - HIV+ not on
ART
1
(100%)
Smear microscopy (AFB) negative;
Xpert MTB+,
TB treatment on basis of
GeneXpert results
8 3 (2–19) HIV+ on ART 4
N = 8 HIV+ not on
ART
1
(100%)
HIV - 3
Smear microscopy (AFB) negative;
Xpert MTB-,
TB treatment on clinical
grounds
13 6 (3–8) HIV+ on ART 6 1 (14%)
N = 165 HIV+ not on
ART
1 1 (50%)
HIV - 2
Unknown 2
Treatment for Bacterial
Infection only
114 2 (0–21) HIV+ on ART 56 3 (5%)
HIV+ not on
ART
4 1 (20%)
HIV - 21
Unknown 27 2 (7%)
No treatment reported 38 - HIV+ on ART 5 8 7 (35%)
HIV+ not on
ART
1 1 (50%)
HIV - 2
Unknown 4 7 3 (21%)
Smear microscopy (AFB) negative—
Xpert result not found,
TB treatment on clinical
grounds
1 24 HIV+ on ART 1
N = 13 Treatment for Bacterial
Infection only
9 0 (0–3) HIV+ on ART 1 3 (75%)
HIV - 3
unknown 1 1
(50%)
No treatment reported 3 - HIV+ on ART 1
unknown 2
Smear microscopy (AFB) negative—.
No Xpert,
TB treatment on clinical
grounds
12 6 (4–8) HIV+ on ART 7 2 (22%)
(Continued)
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Table 4. (Continued)
Diagnostic process Treatment Uptake n = 348 Time to treatment,
median days (IQR)
HIV (ART)
status
LTF Alive Died
N = 113 HIV - 1 1 (50%)
unknown 1
Treatment for Bacterial
Infection only
79 3 (0–29) HIV+ on ART 34 2 (6%)
HIV+ not on
ART
5
HIV - 18
unknown 20
No treatment reported 22 - HIV+ on ART 1 3
HIV+ not on
ART
1
(100%)
HIV - 3
unknown 7 5 2 (14%)
doi:10.1371/journal.pone.0141414.t004
Table 5. Factors associated with Mortality.
Univariate O.R. (95% C.I.) P-value Multivariate O.R. (95% C.I.)* P-value
Gender (male) 2.78 (1.35–5.70) 0.005 2.98 (1.31–6.77) 0.009
Age (per year) 1.01 (0.99–1.04) 0.25
Site**:
ZCH -
MHC 0.56 (0.24–1.33) 0.19
HIV (ART) status at 6 months:
HIV+ on ART 9.43 (1.24–71.5) 0.03 8.33 (1.01–67.2) 0.05
HIV+ not on ART 25.7 (2.8–99.9) 0.004 33.5 (3.26–99) 0.003
HIV- - - - -
unknown 8.33 (1.04–67.0) 0.04 5.3 (0.6–45) 0.13
Duration of cough (in weeks) 1.00 (0.96–1.04) 0.94
Previous TB (yes) 0.53 (0.20–1.40) 0.20
Sputum AFB results
AFB+ 0.42 (0.07–2.46) 0.34
AFB- 0.49 (0.17–1.40) 0.18
no result - -
GeneXpert results
MTB+ 1.84 (0.37–9.25) 0.46
MTB- 1.22 (0.61–2.43) 0.57
no result - -
Having started TB Tx 1.14 (.048–2.74) 0.77
Having started AB Tx 0.10 (0.05–0.22) 0.001 0.11 (0.05–0.24) 0.001
Time to treatment (TB or AB) (in days)*** 0.99 (0.98–1.02) 0.91
* Adjusted for all other variables in the binary logistic regression model. In the multivariable analysis, variables with signiﬁcant associations are shown
only.
** ZCH: Zomba Central Hospital; MCH: Matawale Health Centre
*** for ﬁnal diagnoses; in case that TB and AB treatment were started, time to TB treatment was used
doi:10.1371/journal.pone.0141414.t005
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who have been newly diagnosed with tuberculosis has led to high rates of ascertainment of
HIV status (93% at national level), successful linkage to ART services (95% at national level)
[18] and consequently to improvement in treatment outcomes [19, 20]. However, the cascade
of HIV-TB interventions that leads to better outcomes should start before the diagnosis of TB
is made and our results show that mortality during the diagnostic process is still considerable,
even among outpatients. We found that male gender and being HIV positive-not on ART were
independent risk factors for mortality. Men present later for HIV testing and care and tubercu-
losis diagnosis and treatment than women, and–probably as a consequence—have higher mor-
tality rates during treatment for both conditions. Qualitative research in Malawi indicated that
the perceived paramount importance of men’s role as breadwinner and the associated high
opportunity costs of acknowledging illness may explain delays in seeking care for HIV and TB
[21]. Although being HIV positive-on ART as well as having an HIV unknown status were also
associated with mortality in univariate analyses, only a borderline association of being HIV
positive and on ART remained in the multivariate model.
Not receiving antibiotic treatment was associated with mortality among TB suspects. This
suggests that concomitant severe infections other than TB were important causes of death. A
study conducted in Malawi in 2010 found that bloodstream infections, most involving non-
typhoidal salmonellae, were common among HIV-infected, smear negative patients with fever
and/or weight loss [22]. Receiving antibiotics may also be indirect evidence of more contact
with health care providers leading to more timely treatment interventions. There is no evidence
that the use of antibiotic treatment can lead to false negative results in gene Xpert MTB/RIF.
We did not consistently collect information on the type of antibiotics used and our data did
not allow us to distinguish the impact of antibiotic usage between those with and without a TB
diagnosis. Further studies are required to determine if a routine course of broad-spectrum anti-
biotics is beneficial for patients undergoing investigation in chronic cough registers
In accordance with several other studies in operational settings, we did not see an associa-
tion between XpertMTB/RIF test results and mortality reduction. A multi-center pragmatic
trial from South Africa, Zambia, Zimbabwe and Tanzania found that in comparison with
microscopy-based diagnosis, XpertMTB/RIF testing in primary health care settings allowed TB
treatment to be started more frequently and earlier, but this had no effect on mortality [23]. In
a randomized trial from South Africa, Xpert MTB/RIF testing was also compared with a rou-
tine diagnostic algorithm in a primary health care setting. Xpert MTB/RIF testing led to
increased microbiologically confirmed TB cases, more TB treatment initiations and an earlier
start of TB treatment, but again without any effect on 6-month mortality [24]. In a Ugandan
before/after study, the introduction of XpertMTB/RIF in a hospital setting reduced time to TB
diagnosis, but not time to tuberculosis treatment initiation, and there was no effect on
2-month mortality. Similar to our study, this last study lacked statistical power to study impact
on survival [25]. These studies point to the diagnostic benefits of XpertMTB/RIF, especially in
HIV-infected TB suspects, but leave doubt about clinical benefits. This is probably due to the
fact that clinicians in sub-Saharan Africa are prepared to start empirical TB treatment fre-
quently in AFB smear negative TB suspects, which may also be the case in Malawi. More work
is therefore required to evaluate the impact of XpertMTB/RIF testing in Malawi, especially in
terms of patient outcomes. We did not find any cases of rifampicin resistance, which is consis-
tent with a recent survey that showed that drug resistant TB is as low as 0.4% in new cases in
Malawi [26].
The diagnostic impact of XpertMTB/RIF testing appeared modest in our real-life setting.
This was mainly determined by the low uptake as only 186/328 (57%) of those eligible in both
health facilities underwent Xpert MTB/RIF testing. Although samples from patients at MHC
could be sent for Xpert MTB/RIF testing at the nearby ZCH, only 17% of samples from AFB
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sputum smear negative patients were sent. Apart from the logistical difficulties of sending sam-
ples to another health facility in the case of MHC, other factors may have played a role. Despite
extensive off-site training, health care workers may not have fully understood or applied the
algorithm. The volume of left-over sputum may have been insufficient for Xpert MTB/RIF test-
ing after sputum was used for smear microscopy. Equipment may have been out of order and
cartridges out of stock. A limitation of our study is that it did not address the causes of the low
uptake of XpertMTB/RIF testing. Simplification of the algorithm by using XpertMTB/RIF test-
ing as the primary test for all TB suspects, replacing smear microscopy, could facilitate uptake.
However, in a low-income country like Malawi this option is unlikely affordable.
The prevalence of a positive XpertMTB/RIF test result was low (8/186; 4%) and the contri-
bution of a positive XpertMTB/RIF result to TB diagnosis was moderate: 8/54 (15%). We could
not determine the importance clinicians attached to a negative XpertMTB/RIF result in the
diagnostic work-up. However, the low rate of clinical TB diagnoses among XpertMTB/RIF
negative tuberculosis suspects (13/165; 8%) in combination with the low mortality in this
group (2/165; 1%) suggests that a negative result gave clinicians confidence to diagnose and
treat other conditions successfully.
We believe that our results may be representative for urban and peri-urban sites in Malawi,
where many TB suspects are managed. Given that the TB and HIV services of the Ministry of
Health in the study setting are supported by an NGO with a long-term presence in the area, we
do not expect that results elsewhere in Malawi would be much better.
Conclusion
We found high HIV prevalence in adult Malawian outpatients with presumptive TB. However,
one quarter of patients was not HIV tested and in this group mortality was substantial. The
uptake and impact of XpertMTB/RIF testing on TB diagnosis was limited and did not appear
to influence survival. The new national TB diagnostic algorithm needs reinforcement in these
clinics and its effectiveness requires evaluation on a wider scale.
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